Bonum Therapeutics
Focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.
Launch date
Employees
Market cap
-
Enterprise valuation
€338—507m (Dealroom.co estimates Nov 2022.)
Seattle Washington (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Corporate spinout | |
* | $93.0m | Series A | |
Total Funding | €84.5m |